Ketamine, an anesthetic known for its rapid antidepressant effects, has shown promise in treating severe and treatment-resistant depression, particularly among older adults. Unlike traditional antidepressants that may take weeks to be effective, ketamine can alleviate symptoms within hours. Researchers at Texas A&M University published findings in *Translational Psychiatry*, demonstrating how brain activity responds to the drug over time, particularly in U.S. veterans aged 55 and older.
Read More
In their study, the team observed changes in brain responses following a ketamine infusion at one hour, 24 hours, and seven days. Notably, greater increases in a measure of interconnectivity in the brain at 24 hours were associated with more significant symptom relief observed by day seven. Dr. Sanjay Mathew, head of the Experimental Psychopharmacology of Mood and Anxiety Disorders Lab at Texas A&M, emphasizes the importance of including older adults in research, as they are often underrepresented despite making up over a third of the population.
Previous studies from Mathew's group indicated that intravenous ketamine is both feasible and effective for older adults, paving the way for newer research initiatives focused on the neurological underpinnings of its effects. Dr. Nicholas Murphy, a research associate professor at Texas A&M, highlighted the gap in understanding how ketamine affects aging brains, stating, "Most drug studies end at age 65, leaving relatively little research on how ketamine affects the aging brain."
The recent study involved collaboration with researchers from Baylor College of Medicine and the University of the Balearic Islands and utilized electroencephalography (EEG) to record brain activity following infusion. The investigation sought to examine broader networks of brain signals rather than focusing solely on individual signals or pairs.
Research associate Krisha Shah explained the need to consider the brain as a highly interconnected system, stating, "Ketamine is unusual because the drug exposure is brief, but antidepressant effects have the potential to extend well beyond that experience."
The methodology incorporated higher-order interactions to analyze data from multiple EEG signals, expanding upon earlier research that focused on healthy individuals. Murphy suggested that flexibility in brain connectivity may be more significant for clinical outcomes than the magnitude of the initial brain response to ketamine.
The findings could present biomarkers indicative of ketamine's antidepressant effects, potentially guiding future therapeutic approaches that do not carry the same risks associated with ketamine’s psychedelic or abuse potential. Murphy reiterated, "The goal of the work that my team has been doing is to identify these key points in that physiological roadmap so it can be acted upon via another mechanism that doesn’t have the psychedelic or medical side effects of ketamine."
This study underscores the evolving landscape of ketamine’s application in mental health treatment, particularly for older adults resistant to conventional therapies. It lays the groundwork for further exploration of how brain communication changes with treatment to enhance therapeutic outcomes.